We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

49 hedge funds and large institutions have $131M invested in VanEck Pharmaceutical ETF in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

16% more capital invested

Capital invested by funds: $113M → $131M (+$17.9M)

1% more ownership

Funds ownership: 46.22% → 47.22% (+1%)

6% less funds holding

Funds holding: 52 → 49 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $920K

Holders
49
Holders Change
-3
Holders Change %
-5.77%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
14
Reduced
11
Closed
7
Calls
–
Puts
$920K
Net Calls
-$920K
Net Calls Change
+$323K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$9.18M
2
MIH
Meitav Investment House
Israel
+$8.81M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.74M
4
VF
Virtu Financial
New York
+$1.43M
5
TRCT
Tower Research Capital (TRC)
New York
+$514K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$4.44M
2
ECM
Endurant Capital Management
California
-$1.45M
3
Citigroup
Citigroup
New York
-$1.01M
4
CCT
Country Club Trust
Missouri
-$890K
5
MA
Mutual Advisors
Nebraska
-$823K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$160K -$11.2K -194 -7%
NSIM
27
North Star Investment Management
Illinois
$159K -$406 -7 -0.3%
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$142K – – –
LTFS
29
Ladenburg Thalmann Financial Services
Florida
$119K – – –
JP Morgan Chase
30
JP Morgan Chase
New York
$115K – – –
NL
31
NVWM LLC
Pennsylvania
$89K – – –
AG
32
Advisor Group
Arizona
$86K – – –
TCM
33
Tradewinds Capital Management
Washington
$59K -$11.6K -200 -17%
GT
34
Glenmede Trust
Pennsylvania
$59K – – –
ASN
35
Advisory Services Network
Georgia
$48K +$232 +4 +0.5%
MIM
36
Macroview Investment Management
Maryland
$45K +$58 +1 +0.1%
HCM
37
Highlander Capital Management
New Jersey
$44K – – –
JCM
38
Jacobi Capital Management
Pennsylvania
$26K +$58 +1 +0.2%
WWM
39
Willingdon Wealth Management
North Carolina
$20K – – –
CPA
40
Clear Perspective Advisors
Illinois
$18K – – –
William Blair & Company
41
William Blair & Company
Illinois
$12K – – –
ADL
42
Asset Dedication LLC
California
$10K – – –
IA
43
IFP Advisors
Florida
$9K – – –
CWA
44
Clarus Wealth Advisors
Arizona
$6K +$5.8K +100 New
FANJ
45
Financial Architects (New Jersey)
New Jersey
$4K – – –
AIM
46
Anchor Investment Management
South Carolina
$3.42K – – –
BFEC
47
Benjamin F. Edwards & Company
Missouri
$1K +$58 +1 +5%
CF
48
Centaurus Financial
California
$1K +$927 +16 New
ECM
49
Endurant Capital Management
California
– -$1.45M -25,500 Closed
CCT
50
Country Club Trust
Missouri
– -$890K -15,675 Closed
1
2
3

PPH Hedge Fund Activity: Q2 2018 in Review

49 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2018, worth a combined $131M — up 16% from $113M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PPH and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 14 added.

The largest buyer was Goldman Sachs, adding an estimated $9.18M. The largest seller was Bank of America, cutting an estimated $4.44M.

  • 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2018, down from 52 in Q1 2018.
  • Funds reported $131M of VanEck Pharmaceutical ETF stock for Q2 2018, up 16% quarter-over-quarter.
  • 4 funds opened new VanEck Pharmaceutical ETF positions in Q2 2018 and 7 closed out, a net change of -3 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q2 2018 was Goldman Sachs, an estimated $9.18M added.
  • The largest VanEck Pharmaceutical ETF seller in Q2 2018 was Bank of America, an estimated $4.44M sold.

Based on aggregated 13F filings for Q2 2018.